Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX 103

Next Previous
Drug Profile

TRX 103

Alternative Names: TRX-103

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tr1X
  • Class Anti-inflammatories; Gene therapies; Regulatory T lymphocyte cell therapies
  • Mechanism of Action Interleukin-10 expression stimulants; Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Crohn's disease; Graft-versus-host disease
  • Preclinical Immune-mediated uveitis; Inflammatory bowel diseases

Most Recent Events

  • 20 Feb 2026 Stanford University plans a phase I PEACOCX trial for Uveitis in USA(IV, Infusion) in March 2026 (NCT07427628)
  • 10 Feb 2026 Preclinical trials in Immune-mediated uveitis in USA (unspecified route) prior to February 2026 (Tr1x Bio pipeline, February 2026)
  • 04 Feb 2026 Adverse event, pharmacodynamic and pharmacokinetic data from a phase I trial in Graft versus host disease released by Tr1X

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top